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Abstract Cycloheximide in sublethal doses caused apoptosis in 
liver cells in vivo, inducing c-myc, c-fos, c-jun and p53 genes and 
accumulation of sphingosine, a toxic product of the sphingomye-
lin cycle. These data support the hypothesis that continuous 
synthesis of labile protective proteins is required to restrain 
apoptosis in liver; sphingosine might be important in mediating 
cycloheximide-induced apoptosis as an endogenous modulator of 
protein kinase C activity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Apoptosis, programmed cell death, has been shown to play 
a key role in normal development, differentiation, glandular 
atrophy following hormonal withdrawal and maturation of 
the immune system. Its hallmark biochemical feature is endo-
nuclease activation, giving rise to internucleosomal DNA 
fragmentation. There are also characteristic morphological 
changes, including chromatin condensation, nuclear fragmen-
tation, shrinkage, the formation of dense chromatin masses 
and apoptotic bodies. Cytoplasmic structures are relatively 
preserved (reviewed in [1,2]). 
Apoptosis is an active process which is governed by a signal 
transduction pathway. Up-regulation of c-myc, c-fos and p53 
genes is associated with transmission of the apoptotic signal 
[3,4]. Utilization of the sphingomyelin pathway for induction 
of the apoptotic response has already been demonstrated in a 
large variety of mammalian cells [5-8]. Interference with 
apoptosis appears to be one of the mechanisms leading to 
unrestrained growth and development of cancer. Conversely, 
several chemotherapeutic agents as well as ionizing radiation 
impact their antitumor activities by initiating apoptosis [2,9]. 
While the nature of drug interactions with the cellular target 
has been extensively studied, the mechanism by which chemo-
therapeutic agents induce the apoptotic pathway remains un-
clear. 
Cycloheximide (CHI) is a well-known inhibitor of protein 
synthesis and synergistically increases tumor necrosis factor-a 
(TNF-a) cytotoxicity [10]. In mouse and rat thymocytes and 
in many other cell types, apoptosis requires protein and RNA 
synthesis, suggesting the existence of 'death proteins' [11]. In 
contrast, the HL-60 human leukemia cell line and certain 
TNF-susceptible lines have been shown to undergo increased 
apoptosis when macromolecular synthesis is inhibited, sug-
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gesting that in these cases labile 'protective proteins' may exist 
[12]. Probably, regulation of apoptosis differs with cell type 
and stage of differentiation and does not always require pro-
tein synthesis. 
Here we demonstrate that cycloheximide in sublethal doses 
causes apoptosis in liver cells in vivo, inducing c-myc, c-fos, c-
jun and p53 gene expression and accumulation of sphingosine, 
a toxic product of the sphingomyelin cycle, in liver cell nuclei. 
2. Materials and methods 
Wistar rats weighing 120-150 g were treated with CHI (Serva) at 
single doses of 0.01, 0.05, 0.1 and 0.3 mg per 100 g of body weight; 
these doses are known to inhibit [3H]leucine incorporation into pro-
teins in a dose-dependent manner. 
The livers were removed at various time intervals after administra-
tion of CHI. 
Nuclear fraction from liver cells was prepared as described [13]. The 
purity of nuclear preparations were assessed by electron microscopy 
and marker enzyme assays. 
RNA was isolated from rat livers with the guanidine isothiocyanate 
method [14]. Total RNA (25 ug) was fractionated in 1% agarose gel in 
denaturing conditions, transferred to nitrocellulose filters, and hy-
bridized with plasmids containing inserts of the c-myc, c-fos, c-jun 
or p53 genes and labelled by nick-translation. 
Lipids from liver and nuclei were isolated as described [15]. 
Sphingosine was analyzed by reverse-phase HPLC as its fluorescent 
derivatives (2H-isoindoles) as described [16]. 
Analysis of DNA fragmentation was performed by agarose gel 
electrophoresis. 
3. Results 
3.1. Inhibition of protein synthesis by various doses of 
cycloheximide 
CHI at a sublethal dose (0.3 mg/100 g) inhibits protein 
synthesis to 95% of the control level. Lower doses (0.1 and 
0.05 mg/100 g) decreased the inhibiting effect of CHI on pro-
tein synthesis to 60%. 0.01 mg/100 g of CHI had no effect on 
protein synthesis (Fig. 1). 
3.2. Relationship between the levels of c-myc, c-fos, c-jun and 
p53 gene expression in rat liver and the extent of protein 
synthesis inhibition by cycloheximide 
The 95% inhibition of protein synthesis by a sublethal dose 
of CHI induced short-term superexpression of c-myc, c-fos 
and c-jun genes (Fig. 2). Transcripts of these genes were found 
during a period of 2-A h after CHI injection. At the stage of 
restoration of protein synthesis the mRNA content produced 
by these genes was sharply reduced. The p53 tumor suppres-
sor gene, which is directly involved in the process of pro-
grammed cell death [4], is also activated by a sublethal dose 
of CHI (Fig. 2). In contrast to c-fos and c-myc, the expression 
of the p53 gene is weaker and lasts for a longer time during 
the periods of inhibition, restoration, and activation of pro-
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Fig. 1. Time course of changes in protein synthesis in rat liver cells 
after administration of CHI: 1, 0.01; 2, 0.025; 3, 0.05; 4, 0.1; 5, 
0.3 (mg/100 g). 
tein synthesis (Fig. 2). The decrease of protein inhibition by 
CHI at doses of 0.1 and 0.05 mg/100 g was accompanied by a 
decrease of c-myc and c-fos expression. At a dose of 0.01 mg/ 
100 g CHI failed to inhibit protein synthesis and stimulate c-
myc, c-fos and p53 gene expression [17,18]. 
3.3. Protein synthesis inhibition induces apoptosis in liver cells 
in vivo 
Unlike thymocytes and T-cell lines in which protein syn-
thesis inhibition has been shown to prevent induced apoptosis 
[11,19], we found that CHI at a concentration of 0.3 mg/100 g 
(sublethal dose) caused an increase in DNA fragmentation at 
all time points. Gel electrophoresis showed clear DNA ladders 
with no evidence of random-sized DNA fragments (Fig. 3), 
indicating the occurrence of apoptosis but not necrosis. 
3.4. Morphology of apoptotic liver cells 
By electron microscopy apoptotic liver cells isolated 6 h 
after the administration of CHI showed the condensation of 
chromatin into a more uniform electrodense mass (Fig. 4A), 
the formation of apoptotic bodies (Fig. 4B), condensation of 
cytoplasm and zeiosis (blebbing attributed to untethering of 
the plasma membrane from the cytoskeleton). Disruption of 
the plasma membrane was not observed. 
3.5. Changes in the content of sphingosine in rat liver cells and 
nuclei after treatment with CHI 
It has been found that exposure to sphingosine induced 
DNA fragmentation and morphological changes characteristic 
of apoptosis in various cell lines [20-22]. We examined 
changes in free sphingosine level in the whole hepatocytes 
and their nuclei during treatment of rats with various doses 
of CHI (0.01, 0.05 and 0.3 mg/100 g) for indicated time inter-
vals. The sphingosine level in whole hepatocytes increased 
concomitantly with an increase of c-myc and c-fos gene ex-
pression (Fig. 5). 
The sphingosine level in liver cells 2 h after injection of a 
sublethal dose of CHI was roughly 2-fold greater than that in 
Fig. 2. Time course of c-fos, c-jun, c-myc and p53 gene expression 
after injection of CHI in a sublethal dose. 
untreated cells. The sphingosine content in control liver cells 
was 55 ± 15 ng/mg of protein. On the other hand, the level of 
free sphingosine in livers isolated from rats injected with CHI 
at doses which did not sharply increase gene expression did 
not show any elevation. Sphingosine accumulated consider-
ably in liver cell nuclei 2 h after CHI injection at a sublethal 
dose, exceeding the control values almost 3-fold (Fig. 5). The 
Fig. 3. Time course of apoptotic DNA degradation in liver cells 
after injection of CHI in a sublethal dose. Lane 1, control; lanes 2-
7, 1,2, 3, 4, 6 and 10 h after injection respectively. 
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Fig. 4. Electron micrographs of apoptotic changes observed in mouse liver cells 6 h after injection of a sublethal dose of CHI. A: Condensa-
tion of chromatin in the nucleus. B: Formation of apoptotic bodies, which consist of intact mitochondrion and a fragment of cytoplasm sur-
rounded by the unit membrane. 
content of free sphingosine in control nuclei was 49 ± 9 ng/mg 
of protein. 
4. Discussion 
among other biological processes growth suppression which 
is PKC-independent [22]. For example, sphingosine induces 
dephosphorylation of the Rb protein independent of PKC 
inhibition [24]. The potent and specific activation of Rb by 
Internucleosomal cleavage of DNA is a result of an apop-
totic-specific signal transduction which involves lipid second 
messengers, protein kinases, protein phosphatases, proteases 
and oncoproteins. We have shown that regulation of apopto-
sis in liver cells is different from that in thymocytes, because 
the inhibitor of protein synthesis CHI is able to induce apop-
totic events in liver while apoptosis in thymocytes was inhib-
ited by CHI. CHI-induced apoptosis in liver was detected by 
gel electrophoresis of internucleosomal DNA fragments and 
morphological changes in nuclei and chromatin structure by 
electron microscopy. CHI-mediated apoptotic changes in hep-
atocytes were accompanied by the overexpression of c-myc, c-
fos and c-jun genes and long-term expression of p53 gene. The 
protein products of these genes contribute significantly in 
transducing the apoptotic signal. Concomitantly with this el-
evation of gene expression the sphingosine level also increased 
in the whole hepatocytes and their nuclei. Sphingosine, a me-
tabolite of sphingomyelin turnover, can elicit a variety of cel-
lular responses such as inhibition of growth factor action, 
modulation of receptor function, inhibition of calmodulin-de-
pendent enzymes and promotion of antitumor activity [22]. It 
has been found that sphingosine functions as an inhibitor of 
protein kinase C (PKC) and plays an important role in TNF-
induced apoptosis [6,7,20,21]. PKC inhibitors strongly induce 
apoptosis in certain cell types [23]. Sphingosine regulates 
Fig. 5. Time course of changes in free sphingosine level in hepato-
cytes during treatment of rats with different doses of CHI (1, 0.01; 
2, 0.05; 3, 0.3 mg/100 g) and time course of changes in free sphin-
gosine level in liver cell nuclei after injection of a sublethal dose of 
CHI (4). 
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sphingosine correlates with inhibition of cell growth and with 
arrest at G 0 /G i of the cell cycle. Bcl-2 is known to inhibit 
apoptosis in response to a wide spectrum of agents, like chem-
otherapeutic agents, T N F - a , ionizing radiation and activa-
tion of the FAS receptor [25]. Recently, it was shown that 
apoptosis induced by sphingosine and ^A^-dimethylsphingo-
sine was accompanied by a concomitant decrease of bcl-2 
expression at both R N A and protein levels in HL-60 cells, 
while expression of bcl-XL and bax m R N A was not affected 
[26]. These results suggest that sphingosine may function as an 
endogenous mediator of apoptotic signaling. 
The results of our experiments suggest that continuous syn-
thesis of labile 'protective' proteins is necessary to restrain 
apoptosis in liver. Sphingosine might be important in media-
ting CHI-induced apoptosis as an endogenous modula tor of 
P K C and inhibitor of bcl-2 expression. 
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